Checkpoint Capital’s Corcept Therapeutics CORT Stock Holding History

Checkpoint Capital’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-401,395	Closed	-$14M	–	10
2025 Q4	$14M	Buy	401,395 +9,064	+2%	+$712K	4.36%	5
2025 Q3	$32.6M	Buy	392,331 +48,414	+14%	+$3.5M	10.92%	3
2025 Q2	$25.2M	Buy	343,917 +338,917	+6,778%	+$24.6M	11.76%	3
2025 Q1	$571K	Buy	+5,000	New	+$304K	0.31%	12
2024 Q3	–	Sell	-244,750	Closed	-$7.95M	–	18
2024 Q2	$7.95M	Sell	244,750 -29,026	-11%	-$795K	4.79%	8
2024 Q1	$6.9M	Buy	+273,776	New	+$6.47M	4.61%	8

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Checkpoint Capital's CORT Position: Q1 2026 in Review

Checkpoint Capital sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 401,395 shares — an estimated $14M sold.

Checkpoint Capital first reported a position in CORT in Q1 2024 and held it in 6 quarters. The position peaked at $32.6M in Q3 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

Checkpoint Capital reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
Checkpoint Capital sold 401,395 Corcept Therapeutics shares in Q1 2026, an estimated $14M.
Checkpoint Capital first reported a position in Corcept Therapeutics in Q1 2024 and held it in 6 quarters.
Checkpoint Capital's Corcept Therapeutics position peaked at $32.6M in Q3 2025.
351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Checkpoint Capital's 13F filing for Q1 2026, filed 15 May 2026.